SG11201607368XA - Vaccine delivery systems using yeast cell wall particles - Google Patents
Vaccine delivery systems using yeast cell wall particlesInfo
- Publication number
- SG11201607368XA SG11201607368XA SG11201607368XA SG11201607368XA SG11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA
- Authority
- SG
- Singapore
- Prior art keywords
- cell wall
- delivery systems
- yeast cell
- vaccine delivery
- wall particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 210000005253 yeast cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948503P | 2014-03-05 | 2014-03-05 | |
| US201462060124P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/018728 WO2015134606A1 (en) | 2014-03-05 | 2015-03-04 | Vaccine delivery systems using yeast cell wall particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607368XA true SG11201607368XA (en) | 2016-10-28 |
Family
ID=54055837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607368XA SG11201607368XA (en) | 2014-03-05 | 2015-03-04 | Vaccine delivery systems using yeast cell wall particles |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US10166195B2 (en) |
| EP (2) | EP3932392A1 (en) |
| JP (3) | JP6797022B2 (en) |
| KR (1) | KR102060858B1 (en) |
| CN (1) | CN106456532B (en) |
| AU (3) | AU2015227226B2 (en) |
| CA (2) | CA2941633C (en) |
| SG (1) | SG11201607368XA (en) |
| WO (1) | WO2015134606A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015227226B2 (en) * | 2014-03-05 | 2017-10-05 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2017027568A1 (en) * | 2015-08-11 | 2017-02-16 | Orbis Health Solutions Llc | Bacterial and viral vaccine strategy |
| CN107233298B (en) * | 2016-03-28 | 2021-01-22 | 复旦大学 | Yeast cell wall particle preparation for promoting oral absorption of protein polypeptide medicine |
| CN113143977B (en) * | 2021-04-16 | 2022-04-05 | 苏州大学 | Yeast cell wall nano-particle and preparation method and application thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454110A (en) | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
| US4563351A (en) | 1983-08-01 | 1986-01-07 | Forsyth Dental Infirmary For Children | Self-gelling therapeutic compositions for topical application |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| JP3272891B2 (en) | 1994-11-22 | 2002-04-08 | カネボウ株式会社 | Bath additive |
| WO1999030629A1 (en) | 1997-12-17 | 1999-06-24 | Hemodynamics, Inc. | Sealing media for surgery and wound closure |
| US20050158856A1 (en) | 1999-04-20 | 2005-07-21 | Edelson Richard L. | Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials |
| US6342203B2 (en) | 1999-10-27 | 2002-01-29 | Dakota Dental Development, Inc. | Compositions for dentistry comprising an oil, to repair, restore, adhere to, or protect the surface of a tooth |
| US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| ATE336723T1 (en) | 2001-01-18 | 2006-09-15 | Univ Newcastle Ventures Ltd | BIOSENSOR WITH COVALENTLY BONDED MEMBRANE-spanning proteins |
| KR101803702B1 (en) | 2001-09-06 | 2017-12-01 | 노쓰웨스트 바이오써라퓨틱스, 인크. | Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response |
| WO2004014320A2 (en) | 2002-08-13 | 2004-02-19 | Biopolymer Engineering, Inc. | Methods of using beta glucan as a radioprotective agent |
| US20060165700A1 (en) | 2002-09-04 | 2006-07-27 | Ostroff Gary R | Cancer therapy using whole glucan particles and antibodies |
| CN100363054C (en) * | 2002-09-04 | 2008-01-23 | 生物聚合物工程有限公司 | Cancer therapy using whole glucan particles and antibodies |
| US7943179B2 (en) | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
| ES2461178T3 (en) | 2004-05-20 | 2014-05-19 | Eden Research Plc | Hollow glucan or cell wall particle that encapsulates a terpene component |
| US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| CN101052383B (en) | 2004-09-17 | 2013-01-30 | 马萨诸塞大学 | Compositions and their uses for lysosomal enzyme deficiencies |
| JP2008516610A (en) | 2004-10-18 | 2008-05-22 | グローブイミューン，インコーポレイテッド | Treatment of chronic hepatitis C infection using yeast |
| WO2006047515A2 (en) | 2004-10-25 | 2006-05-04 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2007050643A2 (en) | 2005-10-24 | 2007-05-03 | University Of Massachusetts | Compositions and their uses for gene therapy of bone conditions |
| AU2006321415B2 (en) | 2005-11-30 | 2012-11-08 | Cornell University | Terpene-containing compositions and methods of making and using them |
| KR20240005984A (en) | 2005-12-08 | 2024-01-12 | 노쓰웨스트 바이오써라퓨틱스, 인크. | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
| AU2007212076B2 (en) | 2006-02-02 | 2012-10-18 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| WO2008027580A2 (en) | 2006-09-01 | 2008-03-06 | University Of Louisville | PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS |
| US20100111985A1 (en) | 2007-04-25 | 2010-05-06 | Orbis Health Solutions, Llc | Vaccine compositions and methods of use |
| EP2222283A2 (en) | 2007-10-29 | 2010-09-01 | University of Massachusetts | Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna) |
| CN102006891B (en) | 2008-02-13 | 2017-04-26 | 哈佛学院董事会 | Continuous cell programming devices |
| WO2009155332A1 (en) | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| WO2011053331A1 (en) | 2009-11-02 | 2011-05-05 | Orbis Health Solutions Llc | Vaccine compositions and methods of use |
| WO2011088155A2 (en) | 2010-01-12 | 2011-07-21 | Purdue Research Foundation | Materials and methods for producing cell-surface directed and associated non-naturally occurring bioinorganic membranes and uses thereof |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| ES2614181T3 (en) * | 2010-08-14 | 2017-05-30 | University Of Massachusetts | Yeast cell wall particle for delivery of nanoparticles addressed to the receiver |
| BR112013014673A2 (en) | 2010-12-13 | 2016-08-02 | Colgate Palmolive Co | oral compositions |
| US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| WO2014093454A1 (en) | 2012-12-12 | 2014-06-19 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
| PH12013000256A1 (en) | 2013-08-30 | 2015-03-09 | Anacleto M Argayosa | Oral vaccine |
| AU2015227226B2 (en) | 2014-03-05 | 2017-10-05 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| US20180228885A1 (en) | 2016-03-04 | 2018-08-16 | Orbis Health Solutions Llc | Bacterial and viral vaccine strategy |
-
2015
- 2015-03-04 AU AU2015227226A patent/AU2015227226B2/en active Active
- 2015-03-04 CN CN201580022772.8A patent/CN106456532B/en active Active
- 2015-03-04 JP JP2016555517A patent/JP6797022B2/en active Active
- 2015-03-04 US US15/123,479 patent/US10166195B2/en active Active
- 2015-03-04 EP EP21173240.9A patent/EP3932392A1/en not_active Withdrawn
- 2015-03-04 KR KR1020167027182A patent/KR102060858B1/en active IP Right Grant
- 2015-03-04 CA CA2941633A patent/CA2941633C/en active Active
- 2015-03-04 SG SG11201607368XA patent/SG11201607368XA/en unknown
- 2015-03-04 EP EP15758254.5A patent/EP3113759B1/en active Active
- 2015-03-04 CA CA3099413A patent/CA3099413A1/en active Pending
- 2015-03-04 WO PCT/US2015/018728 patent/WO2015134606A1/en active Application Filing
-
2016
- 2016-08-31 US US15/252,999 patent/US20170007688A1/en not_active Abandoned
-
2018
- 2018-01-05 AU AU2018200092A patent/AU2018200092B2/en not_active Ceased
- 2018-12-20 US US16/227,468 patent/US10675249B2/en active Active
-
2019
- 2019-07-05 JP JP2019125837A patent/JP6914996B2/en active Active
- 2019-11-06 US US16/676,395 patent/US11826476B2/en active Active
-
2020
- 2020-05-20 AU AU2020203274A patent/AU2020203274A1/en not_active Abandoned
- 2020-06-05 US US16/893,986 patent/US11179343B2/en active Active
-
2021
- 2021-07-14 JP JP2021116027A patent/JP7311560B2/en active Active
- 2021-11-22 US US17/532,656 patent/US11759429B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3188843A4 (en) | Electrostatic fluid delivery system | |
| EP3137272C0 (en) | Mortar delivery system | |
| PL3188717T4 (en) | Formulation comprising particles | |
| EP3018745B8 (en) | Fuel cell system | |
| EP3212173A4 (en) | Delivery systems | |
| HK1243340A1 (en) | Delivery across cell plasma membranes | |
| GB201410270D0 (en) | Cell delivery system and method | |
| EP3101722A4 (en) | Fuel cell system | |
| PT3136841T (en) | Fermentation systems | |
| GB201419607D0 (en) | Fuel delivery system | |
| SG11201700043XA (en) | Fuel cell system | |
| EP3214685A4 (en) | Fuel cell system | |
| EP3166671A4 (en) | Metal-organic framework materials in gases delivery systems | |
| SG11201607368XA (en) | Vaccine delivery systems using yeast cell wall particles | |
| EP3214687A4 (en) | Fuel cell system | |
| ZA201608085B (en) | Grout delivery | |
| IL252972A0 (en) | Antigen delivery system | |
| EP3174145A4 (en) | Fuel cell system | |
| AU2015225914B2 (en) | Microneedle based cell delivery | |
| GB2533265B (en) | Fuel cell system | |
| EP3109932A4 (en) | Fuel cell system | |
| IL247106B (en) | Substance delivery system | |
| EP3161101A4 (en) | Proppant-based chemical delivery system | |
| EP3118922A4 (en) | Fuel cell system | |
| GB2539606B (en) | Fuel cell system |